Form D · Biotechnology

Navrogen Inc.

Cheyney, PA · CIK 0001756608

Offering snapshot reported Jun 28, 2024 · SEC filing

Reported sold: $542K
Investors reported: 13
Minimum accepted: $5K
First sale: Jun 5, 2024

Fundraising history

Reported sold

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Jun 28, 2024	Amendment	$542,000	$0vs Jun 27, 2024	13	SEC filing
Jun 27, 2024	Initial	$542,000	No comparison	13	SEC filing
Feb 27, 2023	Amendment	$9,059,161	$2,103,887vs Aug 12, 2021	20	SEC filing
Aug 12, 2021	Initial	$6,955,274	No comparison	Not reported	SEC filing
Sep 23, 2019	Amendment	$3,200,000	$1,875,000vs Oct 23, 2018	18	SEC filing
Oct 23, 2018	Initial	$1,325,000	No comparison	9	SEC filing

Offering details

Securities: Other
Exemptions: 06b
Duration over one year: No
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-517111

Convertible Debt

none

Source: Form D, filed Jun 28, 2024. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Allan Bedwick	Director
Luigi Grasso	Director, Executive
Steven G Kyriakos	Executive
Leon O Moulder, Jr	Director
Leon O. Moulder, Jr.	Director
Nicholas C. Nicolaides	Director, Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:

1837 University Cir. Science Center Room 218
Cheyney, PA, 19319